This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated NOX4 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-NOX4 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~66.9 kDa | |
| Observed band | 67-80 kDa | |
| Gel | 10–12% | |
| Negative control | siRNA / KO lysate |
| PTM | Glycosylated | |
| Caveat | N-linked glycosylation | |
| Regulation | LPS-induced | |
| Isoform | 9 isoform(s) |
Literature-validated Western blot parameters for NOX4 — gel percentage, transfer, blocking, antibody incubation and detection, extracted from published methods.
| Sample / lysate | human 293T , Lane 2: human U87 , Lane 3: human SH-SY5Y , Lane 4: human U251 , Lane 5: human U2OS , Lane 6: human Hela , Lane 7: human T47D , Lane 8: monkey COS-7 . After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-NOX4 antigen affinity purified polyclonal antibody (Catalog # A00403) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for NOX4 at approximately 65 kDa. The expected band size for NOX4 is at 67 kDa |
| Gel % | 10–12% |
| Load | 30 ug |
| Transfer | nitrocellulose membrane, 150 mA, 50–90 min |
| Membrane | nitrocellulose |
| Blocking | 5% non-fat milk / TBS, 1.5 h RT |
| Primary antibody | 0.5 µg/mL |
| Primary incubation | overnight at 4 °C |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 |
| Wash | TBS-0.1% Tween, 3 × 5 min |
| Detection | ECL |
| Exposure / imaging | Tanon 5200 |
| Observed band | 65 kDa |
NOX4 has a 66.9 kDa core mass but runs at 67-80 kDa on blots due to N-glycosylation at Asn133 and Asn230, with its 9 splice isoforms adding potential band complexity.
| single band around 67-80 kDa | the native, N-glycosylated form of NOX4 running above its 66.9 kDa core mass |
| diffuse or smeared band spanning roughly 67-80 kDa rather than a sharp line | heterogeneous carbohydrate loading on the two N-glycosylation sites (Asn133, Asn230) |
| closely spaced doublet within the 67-80 kDa range | partial versus full occupancy of the two annotated N-glycosylation sites |
| extra band(s) at a molecular weight distinct from the main 67-80 kDa band | detection of a different NOX4 splice isoform among the 9 annotated isoforms |
| sharp band sitting right at 66.9 kDa with no upward shift | an unmodified, non-glycosylated NOX4 backbone, e.g. bacterially expressed recombinant protein |
| predicted core mass (66.9 kDa) | sets the baseline unmodified backbone size before any post-translational modification is added |
| N-glycosylation at Asn133 and Asn230 | adds carbohydrate mass that shifts the apparent band up into the observed 67-80 kDa range |
| nine annotated splice isoforms (1-9) | alternative splicing can generate additional bands at sizes relatively smaller or larger than the canonical form |
| non-glycosylated bacterial recombinant standard | lacking glycosylation machinery, it runs closer to the unmodified 66.9 kDa mass, lower than native glycosylated NOX4 |
| Situation | Likely cause | Next action |
|---|---|---|
| Band higher than expected | heavy N-glycosylation at Asn133 and Asn230 pushes the band toward the upper end of the 67-80 kDa range | reference the empirical 67-80 kDa range rather than the raw 66.9 kDa predicted mass, and confirm with glycosidase treatment if needed |
| Broad smear instead of sharp band | heterogeneous glycan occupancy and branching at the two N-glycosylation sites | treat lysate with PNGase F or run a longer, lower-voltage separation to resolve the glycoforms into a tighter band |
| Multiple bands | cross-reactivity with different NOX4 splice isoforms among the 9 annotated forms, or partial glycosylation states | verify the dominant 67-80 kDa band matches the expected pattern and check the antibody epitope against isoform sequences |
| Band lower than expected | using a non-glycosylated bacterial-expressed recombinant NOX4 as the size reference | compare native lysate bands only to glycosylated, mammalian-expressed NOX4 controls, not bacterial recombinant standards |
| Weak or no signal | NOX4 is a multi-pass membrane protein residing in the ER and cell membrane, so incomplete solubilization can leave it in the insoluble pellet | use a lysis buffer with sufficient detergent for membrane protein extraction and avoid over-clearing the lysate before loading |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|
| Tissue | Cell type | Level | Evidence | Source |
|---|
Deeper troubleshooting and optimisation questions for NOX4, answered from its protein features.
BosterBio's NOX4 antibodies are among the best-performing WB antibodies on the market — well cited, thoroughly validated, and orthogonally cross-validated against negative tissues and complementary methods.
Our recommended anti-NOX4 antibodies are top-performing, extensively cited reagents, thoroughly validated by Western blot and orthogonally cross-checked against negative tissue and complementary detection methods, delivering confident, reproducible detection of NOX4 expression across sample types.
Which to pick: For NOX4 WB, favor A00403 — its cue is an authentic NOX4 Western blot validation image. PA1929's listed image actually depicts PLA2R/oxidative-stress work, not a NOX4 blot, so treat it as secondary until NOX4-specific data is confirmed.